Is Thermo Fisher Scientific, Inc. overvalued or undervalued?

As of 23 April 2025, the valuation grade for Thermo Fisher Scientific, Inc. has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued. Key ratios include a P/E ratio of 26, an EV to EBITDA of 18.39, and a ROE of 13.42%.
In comparison to peers, Thermo Fisher's P/E ratio of 24.86 is lower than Abbott Laboratories at 19.12 and significantly lower than Intuitive Surgical, which is very expensive at 73.45. The PEG ratio of 4.99 suggests that while growth expectations are high, the stock may still offer value relative to its earnings growth potential. Notably, the company's stock has underperformed against the S&P 500 over the past year, which reinforces the case for its current undervaluation.